Enlivex Therapeutics Ltd.
ENLV
$1.09
$0.1414.20%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -18.04% | 45.89% | 33.31% | -98.92% | 15.96% |
| Total Depreciation and Amortization | -4.71% | -5.56% | 150.00% | -77.64% | 0.63% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -19.61% | 152.15% | -305.71% | -70.86% | 132.16% |
| Change in Net Operating Assets | -202.33% | 136.60% | -170.04% | 144.82% | -362.63% |
| Cash from Operations | -64.27% | 74.09% | -13.22% | -56.06% | -45.63% |
| Capital Expenditure | -200.00% | 78.13% | 8.57% | -288.89% | 43.75% |
| Sale of Property, Plant, and Equipment | 32.38% | -27.38% | 13.51% | -83.30% | 177,100.00% |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 322.24% | -71.00% | -7.36% | 946.17% | 53.02% |
| Cash from Investing | 256.88% | -66.31% | -5.51% | 140.37% | 275.94% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -- | -89.36% | 662.80% | -94.32% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | 200.00% | 99.07% | -- | -- |
| Cash from Financing | -- | -100.00% | -84.38% | 404.40% | -94.34% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 1,804.65% | 89.71% | -334.39% | 155.15% | -153.06% |